Jun 11, 2026 04:23AM
May 4, 2026 04:30PM
Mar 17, 2026 07:12AM
Feb 12, 2026 04:30PM
Dec 21, 2025 04:00AM
Dec 16, 2025 12:00PM
Dec 9, 2025 11:57AM Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Nov 19, 2025 10:06AM
Nov 10, 2025 08:00AM
Oct 31, 2025 09:54AM
Oct 24, 2025 08:29AM
Aug 4, 2025 04:15PM
May 6, 2025 04:01PM
Apr 11, 2025 05:04AM Goldman Sachs Reiterates Neutral Rating on CRISPR Therapeutics (CRSP)
Apr 4, 2025 01:08PM
Feb 11, 2025 04:01PM
Jan 13, 2025 07:01AM
Jan 13, 2025 07:00AM
Jan 4, 2025 04:00PM
Jan 2, 2025 12:51PM
Dec 9, 2024 12:01PM CRISPR Therapeutics (CRSP) Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
Dec 9, 2024 12:00PM
Jan 16, 2024 04:01PM
Jan 16, 2024 04:01PM
Jan 8, 2024 07:07AM
Jan 8, 2024 07:00AM
Dec 8, 2023 12:55PM
Dec 8, 2023 12:52PM Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Dec 8, 2023 12:09PM
Dec 8, 2023 12:05PM
Dec 8, 2023 11:51AM
Dec 8, 2023 11:20AM
Nov 16, 2023 04:53AM
Nov 16, 2023 01:45AM
Nov 6, 2023 04:15PM CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Nov 1, 2023 05:47AM
Oct 31, 2023 05:53PM
Oct 31, 2023 07:10AM
Oct 31, 2023 07:05AM
Aug 7, 2023 04:01PM
Jun 9, 2023 05:35AM
Jun 9, 2023 05:29AM Vertex Pharma (VRTX) Reports Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease
Jun 9, 2023 03:01AM
Jun 8, 2023 07:23PM
May 8, 2023 04:01PM
Apr 3, 2023 08:01AM
Apr 3, 2023 08:00AM
Feb 21, 2023 04:01PM
Dec 12, 2022 10:00AM CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
Dec 10, 2022 08:00AM

323,442 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All